ARWR
ARROWHEAD PHARMACEUTICALS, INC.
FDA PDUFA Target Action Date
Tuesday, November 18, 2025
137 days ago
approved Drug Information
- Indication
- Familial chylomicronemia syndrome (FCS)
- Approved As
- REDEMPLO →
Filing Details
- Company
- ARROWHEAD PHARMACEUTICALS, INC.
- Stock Ticker
- ARWR
- SEC CIK
- 0000879407
- Source
- Company IR →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Track All FDA Decisions
View all upcoming PDUFA dates and AdCom meetings on our FDA Calendar.
View FDA Calendar →Data sourced from SEC EDGAR filings. Last updated: 2025-10-10. Report an issue